Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20794179 | 0.90 | CETP (0.63) | CETPNR1I2 | |
| SCHEMBL17546257 | 0.90 | CETP (0.66) | CETPNR1I2 | |
| SCHEMBL9955359 | 0.89 | CETP (0.62) | CETPNR1I2 | |
| SCHEMBL29786762 | 0.89 | CETP (0.64) | CETPNR1I2 | |
| SCHEMBL9955476 | 0.89 | CETP (0.62) | CETPNR1I2 | |
| SCHEMBL9957610 | 0.89 | CETP (0.62) | CETPNR1I2 | |
| SCHEMBL531582 | 0.89 | CETP (0.64) | CETPNR1I2 | |
| SCHEMBL14016076 | 0.87 | CETP (0.62) | CETPNR1I2 | |
| SCHEMBL14016077 | 0.87 | CETP (0.60) | CETPNR1I2 | |
| SCHEMBL20780441 | 0.86 | CETP (0.57) | CETPNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160075724-A1 | CETP Inhibitors | MERCK SHARP & DOHME (US) | 2016-03-17 | — | — | US | disclosed |
| US-9212118-B2 | Synthesis of intermediates for preparing anacetrapib and derivatives thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-12-15 | — | — | US | disclosed |
| US-8865707-B2 | Cholesteryl ester transfer protein inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865707-B2 | Cholesteryl ester transfer protein inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865707-B2 | Cholesteryl ester transfer protein inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140135368-A1 | SYNTHESIS OF INTERMEDIATES FOR PREPARING ANACETRAPIB AND DERIVATIVES THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2014-05-15 | — | — | US | disclosed |
| EP-1942904-A2 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | Merck & Co., Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| WO-2007081570-A2 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007041494-A2 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | MERCK & CO., INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041494-A2 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | MERCK & CO., INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| EP-1765793-A1 | CETP INHIBITORS | Merck and Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060040999-A1 | CETP inhibitors | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| WO-2006014413-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221383-A1 | CETP INHIBITORS | CETP, APOB, MTTP | CETP 1/4885NR1I2 67/4885 |
| US-20060040999-A1 | CETP inhibitors | CETP, APOB, MTTP | CETP 1/4885NR1I2 67/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | CETP 1/4885NR1I2 67/4885 |
| US-20140135368-A1 | SYNTHESIS OF INTERMEDIATES FOR PREPARING ANACETRAPIB AND DERIVATIVES THEREOF | CYP2B6, CYP4B1, CIAPIN1 | CETP 669/4885NR1I2 1037/4885 |
| US-20160075724-A1 | CETP Inhibitors | CETP, APOB, MTTP | CETP 1/4885NR1I2 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.